Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced that it has finalized an amended protocol to the US Food & Drug Administration (FDA) for the company’s Phase 3 clinical trial (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate coronavirus (COVID-19).
The specialty life sciences firm said after the clinical team’s further analysis, the company will now be submitting to the FDA the study’s amended protocol with a new primary efficacy endpoint, specifically, assessing the difference in the proportion of participants with improvement in at least two COVID-19 related clinical symptoms on or before day 14, compared with baseline between Bucillamine versus placebo.
Revive noted additional secondary endpoints may include the time to the polymerase chain reaction resolution, clinical outcome (death or hospitalization), disease severity, supplemental oxygen use, and progression of COVID-19.
READ: Revive Therapeutics says Phase I/II psilocybin clinical study for methamphetamine use disorder will inform late-stage trials of film strip product
It added that should the FDA agree with the revised protocol, the Data Safety Monitoring Board (DSMB) will review the completed post-dose selection data of about 500 subjects in the context of the new primary endpoint.
The DSMB may recommend continuing the study if there is a trend toward achieving statistical significance, halting the study early due to statistical significance likely not going to be met, or halting the study early due to positive efficacy showing statistical significance, according to Revive.
Regardless of the outcome, the company said it would proceed to seek a meeting with the FDA to agree on a proposed plan for potential regulatory approval.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19.
Contact Sean at sean@proactiveinvestors.com